Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study

International audienceAims: To determine the cardiovascular disease (CVD) risk profile of a large UK HIV cohort and how highly active antiretroviral therapy (HAART) affects this. Methods: A cross-sectional study within a large inner city Hospital and neighbouring district hospital. 1021 HIV positive outpatients representative of the complete cohort; 990 had no previous CVD. We recorded demographics, highly active antiretroviral therapy (HAART) history and CVD risk factors. CVD and coronary heart disease (CHD) risks were calculated using the Framingham (1991) algorithm adjusted for family history. Results: The non-CVD cohort (n=990) was 74% male, 51% Caucasian and 73.1% were on HAART. Mean age was 41±9 years, systolic blood pressure 120±14mmHg, total cholesterol 4.70±1.05mmol/L, HDL-C 1.32±0.48 mmol/L and 37% smoked. Median CVD risk (n=973) was 4 (0-56)% in men and 1.4(0-37) % in women; CHD risks were 3.5(0-36)% and 0.6(0-16)%. CVD risk was >20% in 6% of men and 1% of women and >10% in 12% of men and 4% of women. CVD risk was higher in Caucasians than other ethnicities; the risk factor contributing most was raised cholesterol. For patients on their first HAART, increased CHD risk (26.2% vs. 6.5%; odds ratio 4.03, p<0.001) was strongly related to duration of therapy. Conclusions: Modifiable risk factors, especially cholesterol, and also duration of HAART, were key determinants of CVD risk. Discussion: Regular CHD and/or CVD risk assessment should be performed on patients with HIV. The effect of different HAART regimens on CHD risk should be considered when selecting therapy. Clinical Trials.gov identifier: NCT010509

Suivi thérapeutique pharmacologique du méthotrexate à faible dose dans le traitement des maladies inflammatoires

RENNES1-BU Santé (352382103) / SudocSudocFranceF

La dépression chez la personne âgée (traitements pharmacologiques)

RENNES1-BU Santé (352382103) / SudocLYON1-BU Santé (693882101) / SudocSudocFranceF

Comparative Efficacies of Antibiotics in a Rat Model of Meningoencephalitis Due to Listeria monocytogenes

The antibacterial activities of amoxicillin-gentamicin, trovafloxacin, trimethoprim-sulfamethoxazole (TMP-SMX) and the combination of trovafloxacin with TMP-SMX were compared in a model of meningoencephalitis due to Listeria monocytogenes in infant rats. At 22 h after intracisternal infection, the cerebrospinal fluid was cultured to document meningitis, and the treatment was started. Treatment was instituted for 48 h, and efficacy was evaluated 24 h after administration of the last dose. All tested treatment regimens exhibited significant activities in brain, liver, and blood compared to infected rats receiving saline (P < 0.001). In the brain, amoxicillin plus gentamicin was more active than all of the other regimens, and trovafloxacin was more active than TMP-SMX (bacterial titers of 4.1 ± 0.5 log(10) CFU/ml for amoxicillin-gentamicin, 5.0 ± 0.4 log(10) CFU/ml for trovafloxacin, and 5.8 ± 0.5 log(10) CFU/ml for TMP-SMX; P < 0.05). In liver, amoxicillin-gentamicin and trovafloxacin were similarly active (2.8 ± 0.8 and 2.7 ± 0.8 log(10) CFU/ml, respectively) but more active than TMP-SMX (4.4 ± 0.6 log(10) CFU/ml; P < 0.05). The combination of trovafloxacin with TMP-SMX did not alter the antibacterial effect in the brain, but it did reduce the effect of trovafloxacin in the liver. Amoxicillin-gentamicin was the most active therapy in this study, but the activity of trovafloxacin suggests that further studies with this drug for the treatment of Listeria infections may be warranted

Study of three biocides (dimethoate, ethyl parathion, and zineb) on female rat neuro endocrinological balance

Translated from French (Toxicological European Research 1981 v. 3 no. 6 p. 279-283)Available from British Library Document Supply Centre-DSC:9022.381(HSE-Trans--16074)T / BLDSC - British Library Document Supply CentreSIGLEGBUnited Kingdo